Efficacy among therapeutically effective absorbed dose patients in ReSPECT-GBM phase I of rhenium-186 nanoliposome (186RNL) in recurrent glioblastoma (rGBM) compared to an external control arm (ECA) (SNO 2023) - Nov 11, 2023 - Abstract #BIOS-01; Pres time: Nov 17, 2023; 07:30 PM - 09:30 PM; Location: Exhibit Hall A/B; "Based on prior work establishing the comparability of a bevacizumab (Bev) comparator to inform early-phase CED study results, OS of the 15 TAD patients were compared to a Bev ECA. Single-arm studies can be challenging to interpret. By comparing the ReSPECT-GBM outcomes to an ECA of similar patients with balanced baseline characteristics, we can better appreciate the treatment effect of 186RNL administered via CED. The current results are encouraging, and updated results reflecting current follow-up will be presented at the meeting."
Clinical • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|
|
Lisa Ensign; Norman LaFrance; Lihong Diao; Kala Tummagunta; Denis Boisvert; Joel Michalek; Andrew J. Brenner; Melissa Moore; Marc Hedrick; Ruthanna Davi
|